Diagnosis and Management of Neurosarcoidosis

Diagnostic Approach

The American Thoracic Society recommends that neurosarcoidosis diagnosis requires a compatible clinical syndrome, gadolinium-enhanced MRI findings, histopathologic confirmation of noncaseating granulomas, and rigorous exclusion of alternative diagnoses, including infections, malignancy, and other granulomatous diseases 1, 2
Gadolinium-enhanced MRI of brain and spine is the most sensitive test for neurosarcoidosis and should be performed in all suspected cases, looking for leptomeningeal enhancement, cranial nerve enhancement, parenchymal lesions, or spinal cord involvement 3, 1
Chest imaging (CT scan) to detect bilateral hilar adenopathy and perilymphatic nodules is essential in the diagnostic workup 1, 2
Tissue biopsy showing noncaseating granulomas is essential for diagnosis, with the most accessible extraneural site biopsied first (lung, lymph node, skin) if systemic disease is present 1, 2
The American College of Chest Physicians suggests that CSF analysis has limited diagnostic specificity but helps exclude alternatives, with typical findings including lymphocytic pleocytosis, elevated protein, and elevated CD4:CD8 ratio 3

The American Thoracic Society warns that inadequate exclusion of infections is the most common cause of misdiagnosis, and that assuming all neurologic symptoms in sarcoidosis patients are neurosarcoidosis can lead to diagnostic errors 1
Insufficient monitoring for cardiac involvement, which carries significant mortality risk, requires specific evaluation beyond routine testing 1, 2
The American College of Rheumatology recommends that corticosteroids are the mainstay of initial treatment, with oral corticosteroids for mild-to-moderate cases and high-dose IV methylprednisolone for severe or refractory cases 1
Steroid-sparing agents, such as methotrexate, are frequently required, with TNF inhibitors (infliximab, adalimumab) effective for refractory neurosarcoidosis 1